545 related articles for article (PubMed ID: 22913204)
1. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
[TBL] [Abstract][Full Text] [Related]
4. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
8. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
10. Sustaining platelet counts in chronic ITP.
Nurden AT
Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
[No Abstract] [Full Text] [Related]
11. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
12. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
13. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Stasi R; Evangelista ML; Amadori S
Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Panzer S
Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
[TBL] [Abstract][Full Text] [Related]
16. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan].
Yoshida M; Kanashima H; Nakao T; Ogawa Y; Hino M; Nakane T; Ohta T; Kumura T; Manabe M; Yamamura R; Yamane T
Rinsho Ketsueki; 2013 May; 54(5):444-50. PubMed ID: 23727682
[TBL] [Abstract][Full Text] [Related]
20. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
[Next] [New Search]